Magnolia Neurosciences is a drug discovery and development company focused on the creation of a novel class of neuroprotective medicines. Magnolia endeavors to make life-changing medicines for the benefit of patients and their families suffering from serious CNS diseases.

Magnolia was launched in 2017 with The University of Texas MD Anderson Cancer Center. The company also has a wholly owned subsidiary, Magnolia Tejas Corporation, based in Houston, Texas that is focused on developing a novel therapy for chemotherapy-induced neurological conditions.